Abstract
9501 Background: Zoledronic acid (ZA) given monthly for 24 months (mo) reduces bone pain and skeletal-related events (SRE) in patients (pts) with bone metastases. We tested whether ZA every 3 mo wo...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have